| pubmed-article:21112803 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21112803 | lifeskim:mentions | umls-concept:C0007806 | lld:lifeskim |
| pubmed-article:21112803 | lifeskim:mentions | umls-concept:C0036751 | lld:lifeskim |
| pubmed-article:21112803 | lifeskim:mentions | umls-concept:C0041485 | lld:lifeskim |
| pubmed-article:21112803 | lifeskim:mentions | umls-concept:C0221099 | lld:lifeskim |
| pubmed-article:21112803 | lifeskim:mentions | umls-concept:C0442805 | lld:lifeskim |
| pubmed-article:21112803 | lifeskim:mentions | umls-concept:C0268490 | lld:lifeskim |
| pubmed-article:21112803 | lifeskim:mentions | umls-concept:C0243127 | lld:lifeskim |
| pubmed-article:21112803 | lifeskim:mentions | umls-concept:C0443331 | lld:lifeskim |
| pubmed-article:21112803 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:21112803 | pubmed:dateCreated | 2011-1-18 | lld:pubmed |
| pubmed-article:21112803 | pubmed:abstractText | Psychomotor impairment has been described in hypertyrosinemia types II and III (HT III). Only recently cognitive deficits have also been reported in hypertyrosinemia type I (HT I). The pathogenic mechanisms responsible are unknown. Since implementation of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC, Nitisinone (Swedish Orphan International)) in the treatment of HT I, plasma tyrosine elevation is a common finding as known from the other hypertyrosinemias. | lld:pubmed |
| pubmed-article:21112803 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21112803 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21112803 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21112803 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21112803 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21112803 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21112803 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21112803 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21112803 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21112803 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21112803 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:21112803 | pubmed:issn | 1096-7206 | lld:pubmed |
| pubmed-article:21112803 | pubmed:author | pubmed-author:MayatepekErta... | lld:pubmed |
| pubmed-article:21112803 | pubmed:author | pubmed-author:AssmannBirgit... | lld:pubmed |
| pubmed-article:21112803 | pubmed:author | pubmed-author:Spiekerkoette... | lld:pubmed |
| pubmed-article:21112803 | pubmed:author | pubmed-author:HerebianDiran... | lld:pubmed |
| pubmed-article:21112803 | pubmed:author | pubmed-author:KleeDirkD | lld:pubmed |
| pubmed-article:21112803 | pubmed:author | pubmed-author:ThimmEvaE | lld:pubmed |
| pubmed-article:21112803 | pubmed:copyrightInfo | Copyright © 2010 Elsevier Inc. All rights reserved. | lld:pubmed |
| pubmed-article:21112803 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21112803 | pubmed:volume | 102 | lld:pubmed |
| pubmed-article:21112803 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21112803 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21112803 | pubmed:pagination | 122-5 | lld:pubmed |
| pubmed-article:21112803 | pubmed:meshHeading | pubmed-meshheading:21112803... | lld:pubmed |
| pubmed-article:21112803 | pubmed:meshHeading | pubmed-meshheading:21112803... | lld:pubmed |
| pubmed-article:21112803 | pubmed:meshHeading | pubmed-meshheading:21112803... | lld:pubmed |
| pubmed-article:21112803 | pubmed:meshHeading | pubmed-meshheading:21112803... | lld:pubmed |
| pubmed-article:21112803 | pubmed:meshHeading | pubmed-meshheading:21112803... | lld:pubmed |
| pubmed-article:21112803 | pubmed:meshHeading | pubmed-meshheading:21112803... | lld:pubmed |
| pubmed-article:21112803 | pubmed:meshHeading | pubmed-meshheading:21112803... | lld:pubmed |
| pubmed-article:21112803 | pubmed:meshHeading | pubmed-meshheading:21112803... | lld:pubmed |
| pubmed-article:21112803 | pubmed:meshHeading | pubmed-meshheading:21112803... | lld:pubmed |
| pubmed-article:21112803 | pubmed:meshHeading | pubmed-meshheading:21112803... | lld:pubmed |
| pubmed-article:21112803 | pubmed:meshHeading | pubmed-meshheading:21112803... | lld:pubmed |
| pubmed-article:21112803 | pubmed:meshHeading | pubmed-meshheading:21112803... | lld:pubmed |
| pubmed-article:21112803 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21112803 | pubmed:articleTitle | Increase of CSF tyrosine and impaired serotonin turnover in tyrosinemia type I. | lld:pubmed |
| pubmed-article:21112803 | pubmed:affiliation | Department of General Pediatrics, University Children's Hospital, Heinrich-Heine-University Düsseldorf, Moorenstrasse 5, Düsseldorf, Germany. Eva.Thimm@med.uni-duesseldorf.de | lld:pubmed |
| pubmed-article:21112803 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21112803 | pubmed:publicationType | Case Reports | lld:pubmed |
